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Abstract
Decidualization renders the endometrium transiently receptive to an implanting blastocyst although the underlying
mechanisms remain incompletely understood. Here we show that human endometrial stromal cells (HESCs) rapidly release
IL-33, a key regulator of innate immune responses, upon decidualization. In parallel, differentiating HESCs upregulate the IL-
33 transmembrane receptor ST2L and other pro-inflammatory mediators before mounting a profound anti-inflammatory
response that includes downregulation of ST2L and increased expression of the soluble decoy receptor sST2. We
demonstrate that HESCs secrete factors permissive of embryo implantation in mice only during the pro-inflammatory phase
of the decidual process. IL-33 knockdown in undifferentiated HESCs was sufficient to abrogate this pro-inflammatory
decidual response. Further, sequential activation of the IL-33/ST2L/sST2 axis was disordered in decidualizing HESCs from
women with recurrent pregnancy loss. Signals from these cultures prolonged the implantation window but also caused
subsequent pregnancy failure in mice. Thus, Il-33/ST2 activation in HESCS drives an autoinflammatory response that
controls the temporal expression of receptivity genes. Failure to constrain this response predisposes to miscarriage by
allowing out-of-phase implantation in an unsupportive uterine environment.
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Introduction
For pregnancy to succeed, the human endometrium must first
engage with a competent embryo, embed the conceptus in
decidualizing stroma, and then support deep uterine invasion of
extra-embryonic trophoblast [1,2]. These dynamic events require
a carefully prepared, specialized uterine microenvironment. The
preparatory process for pregnancy starts with the postovulatory
surge in circulating progesterone levels, which in turn inhibits
estrogen-dependent proliferation of the uterine epithelium, induc-
es secretory transformation of the uterine glands, and recruits
uterine natural killer (uNK), macrophages and other immune cells
to the endometrium [3,4,5]. Subsequently, the luminal epithelium
expresses an evolutionarily conserved repertoire of molecules
essential for stable interaction and adherence of a blastocyst, thus
enabling implantation [6,7,8]. Importantly, receptivity is a
transient endometrial state, confined to only a few days in the
mid-secretory phase of the cycle, and dependent on paracrine
signals from stromal cells underlying the luminal epithelium
[9,10]. Failure to express a receptive phenotype is thought to be a
major cause of subfertility and IVF treatment failure [11,12].
Conversely, prolonged endometrial receptivity facilitates implan-
tation of delayed or compromised embryos and has a strong
association with early pregnancy loss [12,13,14]. Thus, the timing
and duration of the so-called ‘window of implantation’ are major
endometrial determinants of the likelihood of reproductive success.
Decidualization denotes the differentiation process by which
resident endometrial stromal cells acquire a specialized secretory
phenotype [15,16]. In fact, secreted factors, such as prolactin
(PRL) and insulin-like growth factor-binding protein 1 (IGFBP1),
are widely used to assess the quality of the decidual response in
human endometrial stromal cells (HESCs) [17]. Hence, decid-
ualization bestows on stromal cells the ability to create paracrine
gradients essential for uterine receptivity and post-implantation
pregnancy support. Decidual cells also function as gatekeepers of
different immune cells at the feto-maternal interface. For example,
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differentiating HESCs secrete interleukin 11 (IL-11) and IL-15,
implicated in recruitment and differentiation of uterine natural
killer (uNK) cells, which in turn are a rich source of angiogenic
factors [18,19,20]. On the other hand, decidual cells surrounding
the early conceptus have been shown to epigenetically silence key
chemokine genes, thus protecting the allogeneic fetus from
infiltrating cytotoxic T lymphocytes [21]. To accomplish this
multitude of functions, decidual cells must adapt dynamically and
Figure 1. The IL-33/ST2L/sST2 axis in decidualizing HESCs. (A) Total ST2 transcript levels were measured in primary HESC cultures treated with
8-bromo-cAMP (cAMP) and MPA for the indicated time-points. (B) ST2L mRNA levels, expressed in arbitrary units (A.U.), were determined in primary
cultures decidualized for 2–8 days (upper panel). Total cell lysates from parallel cultures were probed for ST2L expression (lower panel). b-actin served
as a loading control. (C) The culture supernatant was harvested every 48 h and the levels of accumulated sST2 determined by ELISA. (D) Induction
and release of IL-33 in decidualizing cells. Il-33 mRNA and protein was readily detectable in undifferentiated HESCs. IL-33 mRNA levels increased
rapidly in response to cAMP and MPA (upper panel) but total cellular protein levels gradually declined upon decidualization (lower panel). (E) Il-33
rapidly accumulated in culture supernatant in response to cAMP and MPA signalling (F) HESCs cultured on chamber slides were decidualized for 12 h
and stained for IL-33 expression (green). The nuclei were visualized with DAPI (not shown). The overlayed images were captured by confocal
microscopy. Scale bar: 25 mm. Quantitative data represent the mean (6 SD) of biologically triplicate experiments.
doi:10.1371/journal.pone.0052252.g001
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Figure 2. Representative IL-33 expression in mid-secretory human endometrium. Tissue sections were deparaffinised, rehydrated and
stained with IL-33-specific antibody. A total of 12 biopsies from control subjects were analyzed. (A) Strong nuclear IL-33 immunoreactivity was
observed in both the stromal and epithelial cell compartment (original magnification620). (B) Higher (650) magnification of the indicated area also
shows diffuse cytoplasmic IL-33 staining, especially near the luminal epithelium (C) In some specimens, IL-33 staining was very heterogeneous. For
example, neighboring epithelial cells with a gland could be intensely positive and negative for IL-33 expression. (Scale Bar: 100 mm).
doi:10.1371/journal.pone.0052252.g002
Figure 3. Induction of ST2 and IL-33 expression is differentially regulated. Primary HESC cultures were treated with either 8-br-cAMP or
MPA, in the presence or absence of recombinant IL-33, for 72 hours and (A-C) IL-33, total ST2 and ST2L transcript levels were measured. (D) Secreted
ST2 levels accumulated over 72h were measured using an ELISA. The data represent the mean (6 SD) of biologically triplicate experiments primary
cultures established from 3 different biopsies.
doi:10.1371/journal.pone.0052252.g003
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tailor their secretome to accommodate the various stages of the
implantation process [22]. The mechanisms that control these
transient changes in the phenotype of decidual cells over the
window of implantation are largely unknown. A Th1/Th2
paradigm has been used to describe the changing inflammatory
endometrial microenvironment in early pregnancy [23,24]. While
a Th1-type response, characterized by induction of pro-inflam-
matory cytokines (e.g. IL-2, IL-12 and interferon-c), is thought to
underpin endometrial receptivity and early implantation, a
preponderance of regulatory or anti-inflammatory (Th2-type)
cytokines (e.g. IL-4, IL-5 and IL-10) seems essential for
maintaining pregnancy [25].
IL-33, a member of the IL-1 family, is a key regulator of
inflammatory and immune processes [26,27,28]. It was first
identified as a nuclear factor in endothelial cells. Subsequently it
was shown that IL-33 is a potent pro-inflammatory danger signal,
or alarmin, released from necrotic cells upon trauma or infection
[29]. As a nuclear factor, IL-33 may be involved in transcriptional
repression and regulation of chromatin compaction by promoting
nucleosome-nucleosome interactions [30]. The pro-inflammatory
effects of IL-33, however, require cellular release and binding to its
cell-surface receptor, consisting of ST2, a member of the family of
IL-1 receptor and encoded by IL1LR1, and IL-1R accessory
protein (IL-1RAcP) [26,31]. There are two main ST2 isoforms: a
long transmembrane form (ST2L) and a soluble decoy receptor
(sST2), which lacks both transmembrane and intracellular
domains [26]. ST2L is widely expressed on effector immune cells,
including T lymphocytes, NK and NKT cells, eosinophils,
basophils, and mast cells, enabling IL-33 to drive the host defence
to pathogens and innate immune responses [32]. Secreted sST2
binds and inhibits IL-33, thus serving as a potent anti-inflamma-
tory mediator [26].
Here we report that activation of the IL-33/ST2 pathway in
decidualizing HESCs induces a self-limiting autoinflammatory
response that controls the transient expression of uterine
receptivity genes. We further provide evidence that the ability of
HESCs to restrain this pro-inflammatory response upon decid-
ualization is impaired in patients suffering from recurrent
pregnancy loss (RPL), thus permitting embryo implantation in
an unsupportive uterine environment.
Methods
Patient selection and sample collection
The study was approved by Hammersmith and Queen
Charlotte’s & Chelsea Research Ethics Committee (1997/5065).
Written informed consent was obtained from all patients before
endometrial sampling. Subjects attended the clinic for conception
delay (controls) or RPL and were investigated according to the
standard clinical protocols. RPL was defined as three or more
consecutive pregnancy losses before 24 weeks gestation. Pipelle
biopsies were obtained throughout the cycle or timed to the mid-
secretory phase. An ovulation prediction kit (Assure Ovulation
Predictor, San Diego, CA, USA) was used to obtain samples 6 to
10 days after the pre-ovulatory LH surge (LH+6 to LH+10).
Primary HESC Cultures
HESCs were isolated from endometrial tissues as previously
described [33]. Purified HESCs were expanded in maintenance
medium of DMEM/F-12 containing 10% dextran-coated char-
coal-treated fetal bovine serum (DCC-FBS) and 1% antibiotic-
antimycotic solution. Confluent monolayers were decidualized in
DMEM/F-12 containing 2% DCC-FBS with 0.5 mM 8-bromo-
cAMP (8-br-cAMP; Sigma, Poole, UK) with or without 10–6 M
medroxyprogesterone acetate (MPA; Sigma) to induce a differen-
tiated phenotype. Recombinant human IL-33 was used at 0.1 ng/
ml (R&D Systems, UK). All experiments were carried out before
the third cell passage.
Animal Experiments
C57BL/6 mice were purchased from Charles River Ltd
(Margate, UK) and all experiments were carried out in accordance
with the UK Home Office regulations (PPL70/6867). To prime the
uterus, immature female mice were given hormonal treatment,
consisting of 10 mg/kg/day b-estradiol (Sigma, UK) for three
consecutive days followed by a single dose of 1 mg progesterone
(Sigma, UK). The animals were then anaesthetized, subjected to
laparotomy, and both uterine horns were injected over 5 min with
50 ml of culture supernatant from undifferentiated or decidualized
primary HESCs or control (unconditioned) medium. The cervix
was not clamped. The incision was then closed and the animals were
euthanized 24 h later. The uterine horns were dissected and either
fixed in formalin or snap-frozen and stored at -80uC. To assess
implantation, C57BL/6 female mice were mated with sterile males
and the day of the appearance of the vaginal plug designated as 0
days post coitus (d.p.c.). Laparotomy was performed 2.5 d.p.c. Both
uterine horns were injected with conditioned or unconditioned
culture medium, as described above. After 10 minutes, 10
blastocysts (equivalent of 3.5 d.p.c.) were transferred to a single
treated uterine horn. The uteri were harvested 3 or 6 days following
surgery, ipsilateral implantation sites counted, and tissues fixed in
formalin or snap-frozen for further analysis.
Real-time Quantitative (qRT)-PCR and PCR Arrays
Total RNA was extracted from HESC cultures using Stat60
(Tel-Test, Friendswood, TX, USA). The quality of the RNA was
evaluated using a Bioanalyzer 2100 (Agilent Technologies Inc.,
Santa Clara, CA, USA). Equal amounts of total RNA (2 mg) were
reverse transcribed by using the Superscript First-Strand synthesis
system for RT-PCR (Invitrogen) and the resulting cDNA used as
template in qRT-PCR analysis. The gene-specific primer pairs,
designed by using the Primer3 software, are available on request.
L19 and Cyclophilin represent non-regulated human and murine
genes, respectively, and their expression was used to normalize for
variances in input cDNA. Detection of gene expression was
performed with JumpStart-SYBR Green (Sigma) and the ABI
stepONE Plus sequence detection system (Applied Biosystems,
Foster City, CA, USA). The expression levels of the samples were
expressed as arbitrary units defined by the DDCT method. All
measurements were performed in triplicate. Melting curve analysis
and agarose gel electrophoresis confirmed amplification specificity.
The RT2 Profiler Human Inflammatory mediators and receptors
PCR Array (SA Biosciences), containing 84 genes related to the
inflammatory pathway, plus housekeeping genes and controls, was
used to analyze immune-related gene expression in HESCs. 2 mg of
total RNA was reverse-transcribed with the First Strand kit (SA
Biosciences), combined with the SYBR Green/ROX PCR master
mix (SA Biosciences), and added to each well of the RT2 Profiler
Figure 4. Heat-map representation of the relative change in transcripts encoding inflammatory mediators upon treatment with 8-
Bromo-cAMP and MPA for 2 or 8 days (D2 or D8, respectively). Fold-change is relative to transcript levels in undifferentiated cells. Primary
cultures were established from 3 different biopsies.
doi:10.1371/journal.pone.0052252.g004
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Table 1. Inflammatory mediators regulated upon decidualization in HESCs.
UniGene Interleukins & Receptors Fold-change
D2 D8
Hs.306974 Interleukin 1 family, member 10 (theta) 4.66 -6.81
Hs.516301 Interleukin 1 family, member 5 (delta) 4.48 -8.75
Hs.278910 Interleukin 1 family, member 6 (epsilon) 6.16 -8.56
Hs.166371 Interleukin 1 family, member 7 (zeta) 4.26 -4.69
Hs.278909 Interleukin 1 family, member 8 (eta) 7.02 -12.53
Hs.211238 Interleukin 1 family, member 9 3.00 -42.93
Hs.1722 Interleukin 1, alpha 2.63 -5.33
Hs.126256 Interleukin 1, beta 2.36 5.02
Hs.2247 Interleukin 5 3.06 12.33
Hs.624 Interleukin 8 -1.02 -9.54
Hs.960 Interleukin 9 10.79 -6.34
Hs.193717 Interleukin 10 -3.05 7.03
Hs.845 Interleukin 13 13.25 -7.87
Hs.278911 Interleukin 17C 8.39 -1.72
Hs.287369 Interleukin 22 9.06 -2.09
Hs.81134 Interleukin 1 receptor antagonist 2.43 -8.77
Hs.701982 Interleukin 1 receptor, type I 1.33 -1.06
Hs.68876 Interleukin 5 receptor, alpha 10.44 1.38
Hs.194778 Interleukin 8 receptor, alpha 30.47 2.03
Hs.846 Interleukin 8 receptor, beta 1.16 -58.15
Hs.406228 Interleukin 9 receptor 10.73 -2.31
Hs.504035 Interleukin 10 receptor, alpha 5.99 -1.65
Hs.654593 Interleukin 10 receptor, beta 2.17 1.59
Hs.496646 Interleukin 13 receptor, alpha 1 1.74 -1.37
UniGene Chemokines & Receptors Fold-change
D2 D8
Hs.72918 Chemokine (C-C motif) ligand 1 6.59 -7.38
Hs.54460 Chemokine (C-C motif) ligand 11 -2.69 8.69
Hs.414629 Chemokine (C-C motif) ligand 13 6.72 -1.03
Hs.272493 Chemokine (C-C motif) ligand 15 13.47 -9.50
Hs.10458 Chemokine (C-C motif) ligand 16 15.76 -3.58
Hs.546294 Chemokine (C-C motif) ligand 17 13.68 -2.60
Hs.143961 Chemokine (C-C motif) ligand 18 7.34 -1.37
Hs.50002 Chemokine (C-C motif) ligand 19 9.87 1.66
Hs.303649 Chemokine (C-C motif) ligand 2 1.22 -3.21
Hs.75498 Chemokine (C-C motif) ligand 20 1.86 -8.17
Hs.57907 Chemokine (C-C motif) ligand 21 13.15 -1.44
Hs.169191 Chemokine (C-C motif) ligand 23 16.58 2.20
Hs.247838 Chemokine (C-C motif) ligand 24 3.26 -1.45
Hs.310511 Chemokine (C-C motif) ligand 25 1.89 2.15
Hs.131342 Chemokine (C-C motif) ligand 26 4.15 1.24
Hs.514107 Chemokine (C-C motif) ligand 3 7.97 -1.04
Hs.75703 Chemokine (C-C motif) ligand 4 5.25 -5.43
Hs.514821 Chemokine (C-C motif) ligand 5 6.79 -2.38
Hs.251526 Chemokine (C-C motif) ligand 7 3.90 -1.73
Hs.271387 Chemokine (C-C motif) ligand 8 2.83 -1.01
Hs.632586 Chemokine (C-X-C motif) ligand 10 4.97 -5.31
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PCR plate, containing the pre-dispensed gene-specific primer sets.
The reaction was run on an ABI- stepONE Plus. Data analysis was
based on the CT method, with normalization to four different
housekeeping genes. Measurements were made in triplicate on
primary cultures from 3 subjects.
Table 1. Cont.
UniGene Chemokines & Receptors Fold-change
D2 D8
Hs.632592 Chemokine (C-X-C motif) ligand 11 2.91 -12.83
Hs.522891 Chemokine (C-X-C motif) ligand 12 2.44 2.06
Hs.100431 Chemokine (C-X-C motif) ligand 13 1.53 -6.48
Hs.483444 Chemokine (C-X-C motif) ligand 14 3.08 -1.35
Hs.590921 Chemokine (C-X-C motif) ligand 2 2.72 -7.13
Hs.89690 Chemokine (C-X-C motif) ligand 3 3.23 -5.57
Hs.89714 Chemokine (C-X-C motif) ligand 5 2.23 -4.64
Hs.164021 Chemokine (C-X-C motif) ligand 6 3.16 -3.15
Hs.77367 Chemokine (C-X-C motif) ligand 9 6.21 -14.83
Hs.248116 Chemokine (C motif) receptor 1 10.51 1.17
Hs.78913 Chemokine (C-X3-C motif) receptor 1 10.36 1.14
Hs.789 Chemokine (C-X-C motif) ligand 1 1.85 -5.99
Hs.301921 Chemokine (C-C motif) receptor 1 4.04 -2.58
Hs.511794 Chemokine (C-C motif) receptor 2 10.40 -2.26
Hs.506190 Chemokine (C-C motif) receptor 3 9.44 -1.52
Hs.184926 Chemokine (C-C motif) receptor 4 15.83 -1.45
Hs.450802 Chemokine (C-C motif) receptor 5 18.49 3.16
Hs.46468 Chemokine (C-C motif) receptor 6 9.62 -1.80
Hs.370036 Chemokine (C-C motif) receptor 7 4.70 1.48
Hs.113222 Chemokine (C-C motif) receptor 8 6.07 -1.03
Hs.225946 Chemokine (C-C motif) receptor 9 6.39 -1.67
UniGene Miscellaneous Fold-change
D2 D8
Hs.655285 ATP-binding cassette, sub-family F (GCN20), member 1 2.21 -1.07
Hs.478588 B-cell CLL/lymphoma 6 2.35 1.48
Hs.534255 Beta-2-microglobulin -1.49 11.13
Hs.709456 C-reactive protein, pentraxin-related 21.18 -4.63
Hs.56279 Caspase recruitment domain family, member 18 32.50 3.49
Hs.517106 CCAAT/enhancer binding protein (C/EBP), beta 1.90 -1.03
Hs.592244 CD40 ligand 10.95 1.26
Hs.529053 Complement component 3 2.11 -4.06
Hs.534847 Complement component 4A (Rodgers blood group) 6.51 -1.29
Hs.494997 Complement component 5 4.72 1.17
Hs.412707 Hypoxanthine phosphoribosyltransferase 1 2.26 3.29
Hs.211575 Interferon, alpha 2 6.20 2.44
Hs.655431 Leukotriene B4 receptor 4.08 -1.83
Hs.36 Lymphotoxin alpha (TNF superfamily, member 1) 5.41 -2.93
Hs.376208 Lymphotoxin beta (TNF superfamily, member 3) 3.17 -6.90
Hs.407995 Macrophage migration inhibitory factor 1.06 -1.17
Hs.313 Secreted phosphoprotein 1 2.59 1.57
Hs.591680 Small inducible cytokine subfamily E, member 1 2.09 -1.26
Hs.368527 Toll interacting protein 3.19 1.01
Hs.241570 Tumor necrosis factor (TNF superfamily, member 2) -6.33 9.84
doi:10.1371/journal.pone.0052252.t001
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Transfection and Propidium Iodide Staining
Primary HESCs were transfected with small interfering RNA
(siRNA) by the calcium phosphate co-precipitation method using
the Profection mammalian transfection kit (Promega, Madison,
WI), as previously described [33]. For gene silencing, undifferentiated
HESCs were transiently transfected with 50 nM of the following
siRNA reagents IL1RL1-siGENOME SMARTpool, IL-33-siGEN-
OME SMARTpool, or siCONTROL Non-Targeting purchased
from Dharmacon (Lafayette, CO, USA). Parallel cultures were
harvested in either RIPA buffer for Western blot analysis or washed
with PBS, fixed with cold 70% ethanol, stained with propidium
iodide (Sigma), ribonuclease-A (Qiagen, Germany) treated and
subjected to flow cytometry analysis. The degree of apoptosis in
primary cultures was evaluated by measuring the sub-G1 fraction
(,2N). Transfection studies were performed in triplicate and
repeated on primary cultures from 3 subjects.
Western Blot Analysis
Whole cell protein extracts were prepared by lysing cells in
RIPA buffer. Protein yield was quantified using the Bio-Rad
DC protein assay kit (Bio-Rad, USA). Equal amounts of protein
were separated by 10% SDS-Polyacrylamide Gel Electrophoresis
(SDS-PAGE) before wet-transfer onto PVDF membrane (Amer-
sham Biosciences, UK). Nonspecific binding sites were blocked by
overnight incubation with 5% nonfat dry milk in Tris-buffered
saline with 1% Tween (TBS-T; 130 mmol/L NaCl, 20 mmol/L
Tris, pH7.6 and 1% Tween) as previously described [33]. The
following primary antibodies were used: anti-ST2 and anti-IL-33
Abcam (Cambridge, UK), anti-PARP cleavage site (214/215) from
BioSource International (Camarillo, CA). The primary antibodies
were used at 1:1000 except for the antibodies to b-actin (Abcam),
which was diluted 1:100,000. Protein complexes were visualized
with a chemiluminescent detection kit (GE Healthcare, UK).
Figure 5. Expression of receptivity genes in the mouse uterus in response to HESC signals. The uterine horns of hormonally primed C57B/
6 female mice were injected with either unconditioned medium (UM), culture supernatant from undifferentiated HESCs (D0), or from cultures
decidualized for 4 or 8 days (D4 and D10, respectively). qRT-PCR was used to determine uterine expression 24 h later of the following transcripts:
leukemia inhibitory factor (Lif), interleukin 1-b (Il-1b), heparin binding EGF (Hb-egf), bone morphogenetic protein 2 (Bmp2), wingless-related MMTV
integration site 4 (Wnt4), homeobox protein 10 (Hoxa10), Il-33, trans-membrane ST2 (St2l) and serum- and glucocorticoid-inducible kinase 1 (Sgk1).
Transcript levels were normalized to the levels of Cyclophilin-B (Cyclo) mRNA and expressed in arbitrary units (A.U.). The results represent mean
expression (6 SD). A total of 6 uterine horns were analyzed in each treatment group. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0052252.g005
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Enzyme-linked Immunosorbent Assay (ELISA) for Soluble
ST2 and IL-33
Soluble ST2 and IL-33 levels in the HESC culture media were
determined using an amplified two-step sandwich-type immuno-
assay (DuoSetH; R&D Systems, USA) according to the manufac-
turer’s protocol. Results were derived using the standard curve
method.
Tissue Microarray and Confocal Microscopy
Needle cores (1mm in diameter and 0.4 cm in depth) of the
superficial endometrial layer were obtained from formalin-fixed
and paraffin-embedded timed (LH+5 to +8) endometrial speci-
mens (n = 10) these were arrayed into a recipient block to
construct a tissue microarray. Three mm sections were stained for
IL-33 (1:800; Sigma), as previously described [34]. Stomach was
used as a positive control and the primary antibody was omitted as
a negative control. Immunostaining was visualized using the
MIRAX Viewer (Zeiss, Germany). Immunocytochemistry was
performed on primary HESCs cultured on chamber slides. The
cells were either untreated or treated with 8-br-cAMP for a total of
12 h (Sigma, UK). Cells were fixed in 4% para-formaldehyde and
permeabilized with 0.5% Triton and then incubated overnight at
4uC in a humidified chamber with an anti-IL33 antibody (1:400,
Sigma). The secondary antibody used was Alexa FluorH 488
(1:200; Invitrogen). Slides were mounted with proGOLD (Invitro-
gen) and stained with 4’,6-diamidino-2-phenylindole (DAPI) to
visualize nuclei. Images were captured using a Leica SP5 II
confocal microscope.
Cell Viability Assays
Cultured HESCs were seeded in 96-well black plates with clear
bases and maintained in 10% DCC/DMEM until confluency.
Cells where transfected with or without siRNA targeting IL-33 or
ST2 and then subsequently decidualized or left untreated for a
total of 4 days. Cell viability was evaluated using the CellTiter 96H
AQueous Non-Radioactive Cell Proliferation Assay (MTS)
(Promega) according to the manufacturer’s instructions.
Statistical Analysis
Data were analyzed with the statistical package Graphpad
Prism (Graphpad software Inc). Pearson’s chi-square test,
Student’s t-test and Mann-Whitney U test were used when
appropriate. Logarithmic transformations were used when data
were not normally distributed. Statistical significance was assumed
when P,0.05.
Figure 6. Decidualizing HESCs transiently produce factors permissive of embryo implantation in the mouse uterus. (A) Sterile mated
C57BL/6 female mice were subjected to laparotomy and both uterine horns gently flushed with culture supernatant from undifferentiated HESCs (D0)
or from cultures decidualized for 4 or 10 days (D4 and D10, respectively). Ten embryos (equivalent to stage 3.5 d.p.c.) were then transferred to the
right horn. Each treatment group consisted of 6 animals. The number of implantation sites in the right horn was determined 6.5 d.p.c. Implantation
rate was significantly higher after exposure to signals from D4 compared to D10 or D0 HESCs cells (P,0.001). (B) Macroscopic appearance of uteri at
6.5 d.p.c. (Scale bar; 1 cm). (C) H&E staining of representative implantation sites. Pathological features such as a poor decidual response with pyknotic
and karyorrhectic stromal cell nuclei (arrow heads) were often seen at implantation sites following exposure to soluble factors secreted by D0 HESCs
cells. Implantation sites in uteri pretreated with conditioned medium of D4 HESCs appeared normal, showing trophoblast (T) invasion and
development of large decidual (D) cells. Epithelial cells were also absent from these implantation sites. Petecchia and focal bleeding (arrows heads)
and leukocyte infiltrations (*) were seen at suspect implant sites in uteri pretreated with D10 HESC supernatants. These sites often showed a luminal
epithelium and small, non-decidualized stromal cells, suggestive of failed implantation. (Scale bar: 100 mm).
doi:10.1371/journal.pone.0052252.g006
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Results
The IL-33/ST2L/sST2 Axis in Decidualizing HESCs
IL1RL1 was identified by microarray analysis as being highly
induced in HESCs decidualized with 8-br-cAMP and the
progestin medroxyprogesterone acetate (MPA) for 72 h [35]. It
was also found expressed in baboon endometrium during the
implantation window [36]. To explore the function of this receptor
in the decidual process, we first designed primers to amplify all
ST2 transcripts or selectively ST2L mRNA (Fig. S1). Interestingly,
while decidualization triggered a marked and time-dependent
increase in total ST2 transcripts (Fig. 1A), ST2L mRNA levels
followed a bi-phasic pattern, characterized by strong induction by
2 days of treatment with 8-br-cAMP and MPA followed by a
gradual decline (Fig. 1B, upper panel). This pattern of ST2L
mRNA regulation was mimicked at protein level (Fig. 1B, lower
panel). Analysis of culture supernatants showed that HESCs
secrete increasing amounts of sST2 as the decidual process
proceeds (Fig. 1C). We next tested if HESCs also express IL-33.
Strikingly, the expression of IL-33 transcripts in decidualizing
HESCs paralleled that of ST2L with levels peaking at 2 days of
differentiation (Fig. 1D, upper panel). Western blot analysis
demonstrated that IL-33 is abundantly present in undifferentiated
HESCs yet cellular levels decline rapidly upon decidualization
(Fig. 1D, lower panel). IL-33 levels in culture supernatant
increased 7-fold within 2 days decidualization, indicating that this
inflammatory cytokine/alarmin is actively released by HESCs in
response to cAMP and MPA signalling (Fig. 1E). In support,
confocal microscopy confirmed that IL-33 is almost exclusively
nuclear in undifferentiated cells. Exposure to a decidualizing signal
for 12 h was sufficient to induce IL-33 cytoplasmic foci, suggesting
active secretion (Fig. 1F). Tissue microarray analysis revealed
intense but heterogeneous nuclear IL-33 staining in both epithelial
and stromal cells in mid-secretory endometrium, although there
was evidence of cytoplasmic immunoreactivity in decidualizing
stromal cells underlying the lumen (Fig. 2). Together, the data
show that differentiating HESCs in parallel up-regulate ST2L
expression and release IL-33 before secreting increasing amounts
of sST2.
Convergence of the cAMP and progesterone pathways drives
decidualization of HESCs [5]. To examine how these distinct
pathways impact on the IL-33/ST2L/sST2 axis, primary cultures
were treated for 72 h with 8-br-cAMP or MPA in the presence or
absence of recombinant IL-33. While cAMP signalling stimulated
IL-33 expression, it blunted basal ST2 mRNA levels (Fig. 3A & B).
Recombinant IL-33 modestly enhanced the induction of IL-33
transcripts in response to 8-br-cAMP (Fig. 3A). Conversely, MPA
did not impact on IL-33 levels in HESCs but stimulated expression
of ST2 transcripts (Fig. 3B & C). Interestingly, recombinant IL-33
promoted sST2 secretion at the expense of ST2L mRNA
expression (Fig. 3C & D). Thus, cAMP-dependent IL-33
expression cooperates with progestins to mount an anti-inflam-
matory response, exemplified by up- and down-regulation of sST2
and ST2L, respectively.
Figure 7. ST2 silencing in decidualizing HESCs causes cell death. (A) IL-33 knockdown in HESCs. Confluent primary cultures were
transfected first with non-targeting, ST2, or IL-33 siRNA and then treated with 8-br-cAMP and MPA for 72 h. Whole-cell lysates were immunoprobed
for anti-ST2L, anti-IL-33 and cleaved-poly (ADP-ribose) polymerase (c-PARP). b-actin served as a loading control. (B) Total RNA obtained from parallel
cultures was subjected to qRT-PCR analysis. ST2 but not IL-33 knockdown inhibited the expression of decidual PRL mRNA. (C) In contrast, ST2 as well
as IL-33 knockdown inhibited the induction of IGFBP1 transcripts in decidualizing cell. (D) The viability of HESCs, transfected first with non-targeting
(NT) siRNA, IL-33 or ST2 targeting siRNA and then decidualized, was measured and expressed relatively (%) to the number of viable cells in mock-
transfected, undifferentiated cells (dotted line). (E) The percentage of dead or dying cells (,2N;) and viable cells (G0/G1, S, and G2/M) was determined
by flow cytometry of ethanol-fixed propidium iodide-stained cells. Results are representative of 3 independent experiments. The data represent the
mean (6 SD) of primary cultures established from 3 different biopsies.biologically triplicate experiments.
doi:10.1371/journal.pone.0052252.g007
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A Transient pro-inflammatory Decidual Response Confers
Endometrial Receptivity
The pattern of IL-33 induction in decidualizing HESCs
paralleled that of PROK1, a pro-inflammatory implantation
cytokine [13]. We postulated that bi-phasic regulation could
extend to other inflammatory mediators expressed by differenti-
ating HESCs. To test this hypothesis, we used a qRT-PCR array
to measure the expression of 84 chemokines, cytokines, interleu-
kins, and their receptors in undifferentiated and decidualizing
cultures. Treatment with 8-br-cAMP and MPA for 2 days was
sufficient to significantly up-regulate 70 inflammatory mediators
(.1.5-fold, P,0.01; Fig. 4 & Table 1). At this cut-off, only 3
transcripts (CCL11, IL-10, and TNF-a) were downregulated at this
stage of the decidual process. By 8 days of differentiation, 12
transcripts remained elevated but 34 were now lower compared to
their expression in undifferentiated cells (Table 1 & Fig. S2A).
Thus IL-33 release and induction of its trans-membrane receptor
in HESCs is part of a substantive but transient differentiation-
dependent pro-inflammatory response, involving many chemo-
kines, interleukins, and other mediators.
We speculated that soluble factors secreted by stromal cells
during the pro-inflammatory phase of the decidual process could
serve as signals that render the endometrium receptive. To test this
hypothesis, the conditioned medium of primary HESC cultures
decidualized with 8-br-cAMP and MPA was harvested every 48 h
over 10 days. The uterine lumen of immature C57BL/6 female
mice, primed with progesterone and estradiol, was then flushed at
laparotomy with unconditioned medium, or with culture super-
natant from undifferentiated HESCs, or from cells decidualized
for either 4 or 10 days. The animals were sacrificed 24 h later and
the expression of a panel of uterine receptivity genes examined by
qRT-PCR analysis. Soluble factors accumulated in the superna-
tant of primary cultures decidualized for 4 days up-regulated in
concert Lif, Bmp2, Il-1b, Wnt4, Hb-egf, and Hoxa10 in murine
endometrium (Fig. 5). This response was accompanied by a strong
increase in Il-33 and St2l transcripts. With the exception of Hb-egf
and Hoxa10, the ability of cultured HESCs to generate paracrine
signals that activate receptivity genes had been reduced or lost by
10 days of decidualization. Inhibition of Sgk1 expression and
activity in luminal epithelium is another important feature of the
window of implantation [37]. Conditioned medium from undif-
ferentiated HESCs strongly up-regulated mouse uterine Sgk1
mRNA levels whereas this induction was less pronounced in
response to signals from HESCs decidualized for 4 days (Fig. 5).
To test if decidualizing HESCs control embryo implantation the
uterine flushing experiments were repeated with pseudopregnant
female mice mated with sterile males 2.5 days prior to surgery.
Approximately 10 min after luminal injection of HESC condi-
tioned medium, 10 cultured blastocysts [equivalent of 3.5 days
post coitus (d.p.c)] were transferred into a single uterine horn. The
number of implantation sites was determined 72 h later (equiv-
alent of 6.5 d.p.c). Of the 60 embryos transferred in each
treatment group, 42 (70%) and 45 (75%) embryos failed to
implant upon prior exposure of the uterine lumen to signals from
undifferentiated HESCs or cells decidualized for 10 days,
respectively (Fig. 6A & B). This contrasted to 43 (72%) successful
implantations after flushing with conditioned medium of HESCs
differentiated with 8-br-cAMP and MPA for 4 days. Thus,
decidualizing HESCs transiently produce factors conducive of
pregnancy in this interspecies model. Further, several pathological
features were noted following exposure of the uterine lumen to
secreted factors from undifferentiated HESCs or cells decidualized
for 10 d, including focal bleeding and immune cell infiltration
around the conceptus (Fig. 6C). In contrast, the implantation sites
following exposure to soluble signals from day 4 decidual cells
appeared histologically normal.
Autocrine IL-33 Signaling in HESCs Facilitates Embryo
Implantation
The simultaneous induction of ST2L and release of stored IL-33
suggested activation of an autocrine pathway possibly involved in
coordinating the expression of pro-inflammatory genes in decid-
ualizing cells. To test this conjecture, we used siRNA to silence
ST2L or IL-33 before differentiating primary HESC cultures
(Fig. 7A). ST2L knockdown not only profoundly attenuated
induction of decidual markers, PRL and IGFBP1, but also
compromised the viability of decidualizing cells (Fig. 7B–E). IL-
33 knockdown, however, selectively inhibited the IGFBP1 expres-
sion in response to 8-br-cAMP and MPA stimulation; without
impacting on cell viability (Fig. 7B–E). We therefore monitored the
inflammatory decidual response only following IL-33 knockdown.
While the procedure impacted on the expression of individual
genes, the strong and coordinated induction of chemokines,
cytokines, interleukins, and their receptors was maintained in
primary cultures transfected with non-targeting oligos and treated
with 8-br-cAMP and MPA for 48 h (Fig. 8 & Table 2). IL-33
silencing not only prevented the induction of many pro-
inflammatory genes in decidualizing cells but actively reduced
the expression of several inflammatory mediators, especially
interleukins and chemokines, to levels below those present in
undifferentiated HESCs (Fig. S2B).
We next examined the functional consequences of IL-33
knockdown in HESCs on embryo implantation in the mouse
uterus. Primary HESC cultures were transfected with non-
targeting oligos or IL-33 siRNA and treated with 8-br-cAMP
and MPA for 4 days. Conditioned media accumulated over the
last 48 h were used to flush uteri of pseudopregnant female mice
prior to blastocyst transfer. IL-33 knockdown prior to decidualiza-
tion of HESCs produced supernatants with dire consequences for
pregnancy. These supernatants reduced the implantation rate of
transferred embryos from 90% (45 implantation sites out of 50
transferred embryos) to 14% (7 sites out of 50 transferred embryos;
P,0.001) (Fig. 9A & B). Taken together, the data show that IL-33
knockdown is sufficient to qualitatively transform the initial pro-
inflammatory decidual response into an anti-inflammatory re-
sponse akin to that observed upon prolonged differentiation (Fig.
S2 B). Histological examination demonstrated that uterine
exposure to this altered decidual inflammatory response prior to
embryo transfer jeopardized the subsequent formation of a
functional decidual-placental interface in the few implantation
sites present 6 days later (equivalent of 9.5 d.p.c; Fig. 9C).
The IL-33/ST2L/sST2 Axis is Deregulated in Decidualizing
HESCs from RPL
The decidual response is very divergent between primary
HESC cultures established from RPL and non-RPL subjects
[13,37]. To determine whether the aberrant decidual response
Figure 8. Heat-map representation of the altered expression of decidual inflammatory mediators following IL-33 knockdown. Three
independent primary cultures were transfected with non-targeting (NT) or IL-33 siRNA (si IL-33) prior to treatment with 8-br-cAMP and MPA for 2
days. Fold-change is relative to transcript levels in undifferentiated cells. Primary cultures were established from 3 different biopsies.
doi:10.1371/journal.pone.0052252.g008
IL-33 and Pregnancy Loss
PLOS ONE | www.plosone.org 12 December 2012 | Volume 7 | Issue 12 | e52252
Table 2. Inflammatory mediators regulated decidualizing
HESCs upon transfection with non-targeting (NT) or IL-33
siRNA (si IL-33).
UniGene Interleukins & Receptors Fold-change
NT si IL-33
Hs.306974 Interleukin 1 family, member 10 (theta) 6.24 -31.67
Hs.516301 Interleukin 1 family, member 5 (delta) 16.00-14.22
Hs.278910 Interleukin 1 family, member 6 (epsilon) 34.25-30.37
Hs.166371 Interleukin 1 family, member 7 (zeta) 4.86 -19.11
Hs.278909 Interleukin 1 family, member 8 (eta) 1.10 -29.43
Hs.211238 Interleukin 1 family, member 9 2.02 -35.75
Hs.1722 Interleukin 1, alpha 3.52 24.62
Hs.126256 Interleukin 1, beta 4.30 24.37
Hs.2247 Interleukin 5 (colony-stimulating factor, eosinophil) -4.77 33.68
Hs.624 Interleukin 8 1.37 25.87
Hs.960 Interleukin 9 14.46-28.4
Hs.193717 Interleukin 10 4.09 -15.39
Hs.845 Interleukin 13 2.81 -11.53
Hs.278911 Interleukin 17C 1.12 -11.48
Hs.287369 Interleukin 22 6.14 -23.78
Hs.81134 Interleukin 1 receptor antagonist 3.26 -24.71
Hs.701982 Interleukin 1 receptor, type I 1.78 -23.09
Hs.68876 Interleukin 5 receptor, alpha 33.9811.73
Hs.194778 Interleukin 8 receptor, alpha 40.83-27.25
Hs.846 Interleukin 8 receptor, beta 1.55 -27.47
Hs.406228 Interleukin 9 receptor 9.72 -33.13
Hs.504035 Interleukin 10 receptor, alpha 1.05 13.03
Hs.654593 Interleukin 10 receptor, beta 2.25 -21.98
Hs.496646 Interleukin 13 receptor, alpha 1 3.00 14.42
UniGene & Receptors Fold-change
NT si IL-33
Hs.72918 Chemokine (C-C motif) ligand 1 6.50 -35.29
Hs.54460 Chemokine (C-C motif) ligand 11 -3.60 12.33
Hs.414629 Chemokine (C-C motif) ligand 13 2.67 11.69
Hs.272493 Chemokine (C-C motif) ligand 15 8.72 16.70
Hs.10458 Chemokine (C-C motif) ligand 16 5.45 -27.80
Hs.546294 Chemokine (C-C motif) ligand 17 5.00 12.75
Hs.143961 Chemokine (C-C motif) ligand 18 2.86 16.81
Hs.50002 Chemokine (C-C motif) ligand 19 3.12 -21.17
Hs.303649 Chemokine (C-C motif) ligand 2 1.63 10.05
Hs.75498 Chemokine (C-C motif) ligand 20 3.83 -21.45
Hs.57907 Chemokine (C-C motif) ligand 21 5.29 -34.69
Hs.169191 Chemokine (C-C motif) ligand 23 5.55 -17.77
Hs.247838 Chemokine (C-C motif) ligand 24 1.71 -26.01
Hs.310511 Chemokine (C-C motif) ligand 25 -0.48 -21.21
Hs.131342 Chemokine (C-C motif) ligand 26 1.23 12.81
Hs.514107 Chemokine (C-C motif) ligand 3 2.68 14.06
Hs.75703 Chemokine (C-C motif) ligand 4 3.37 -29.26
Hs.514821 Chemokine (C-C motif) ligand 5 3.09 -26.73
Hs.251526 Chemokine (C-C motif) ligand 7 1.90 12.43
Hs.271387 Chemokine (C-C motif) ligand 8 1.13 15.47
Table 2. Cont.
UniGene Interleukins & Receptors Fold-change
NT si IL-33
Hs.789 Chemokine (C-X-C motif) ligand 1 2.48 -18.83
Hs.632586 Chemokine (C-X-C motif) ligand 10 3.33 -17.01
Hs.632592 Chemokine (C-X-C motif) ligand 11 4.57 -14.84
Hs.522891 Chemokine (C-X-C motif) ligand 12 0.38 10.43
Hs.100431 Chemokine (C-X-C motif) ligand 13 3.27 9.04
Hs.483444 Chemokine (C-X-C motif) ligand 14 2.46 8.77
Hs.590921 Chemokine (C-X-C motif) ligand 2 3.65 -19.15
Hs.89690 Chemokine (C-X-C motif) ligand 3 2.99 10.62
Hs.89714 Chemokine (C-X-C motif) ligand 5 2.98 -33.39
Hs.164021 Chemokine (C-X-C motif) ligand 6 1.90 -24.39
Hs.77367 Chemokine (C-X-C motif) ligand 9 5.99 16.60
Hs.248116 Chemokine (C motif) receptor 1 2.74 -22.37
Hs.78913 Chemokine (C-X3-C motif) receptor 1 3.55 11.06
Hs.301921 Chemokine (C-C motif) receptor 1 2.09 11.39
Hs.511794 Chemokine (C-C motif) receptor 2 3.94 13.78
Hs.506190 Chemokine (C-C motif) receptor 3 3.98 -21.46
Hs.184926 Chemokine (C-C motif) receptor 4 4.88 13.72
Hs.450802 Chemokine (C-C motif) receptor 5 5.44 -29.27
Hs.46468 Chemokine (C-C motif) receptor 6 3.89 10.43
Hs.370036 Chemokine (C-C motif) receptor 7 1.30 -24.64
Hs.113222 Chemokine (C-C motif) receptor 8 2.47 -20.50
Hs.225946 Chemokine (C-C motif) receptor 9 2.23 12.34
UniGene Fold-change
NT si IL-33
Hs.655285 ATP-binding cassette, sub-family F (GCN20)
member 1
2.96 -19.04
Hs.478588 B-cell CLL/lymphoma 6 3.15 -17.29
Hs.534255 Beta-2-microglobulin -2.00 -1.51
Hs.709456 C-reactive protein, pentraxin-related 3.18 14.05
Hs.56279 Caspase recruitment domain family, member 18 43.553.01
Hs.517106 CCAAT/enhancer binding protein (C/EBP), beta 2.55 -31.53
Hs.592244 CD40 ligand 14.67-23.38
Hs.529053 Complement component 3 2.16 -31.10
Hs.534847 Complement component 4A (Rodgers blood group) 1.73 -21.12
Hs.494997 Complement component 5 6.32 -33.68
Hs.412707 Hypoxanthine phosphoribosyltransferase 1 3.03 -24.39
Hs.211575 Interferon, alpha 2 8.30 8.65
Hs.655431 Leukotriene B4 receptor 1.47 -22.35
Hs.36 Lymphotoxin alpha (TNF superfamily, member 1) 4.24 20.78
Hs.376208 Lymphotoxin beta (TNF superfamily, member 3) 2.58 14.55
Hs.407995 Macrophage migration inhibitory factor 1.42 -20.00
Hs.313 Secreted phosphoprotein 1 3.47 -24.40
Hs.591680 Small inducible cytokine subfamily E, member 1 -2.80 13.00
Hs.368527 Toll interacting protein 4.28 -21.12
Hs.241570 Tumor necrosis factor (TNF superfamily, member 2) 0.94 -21.23
doi:10.1371/journal.pone.0052252.t002
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Miscellaneous
associated with RPL also encompasses the IL-33/ST2L pathway,
we established primary HESC cultures from 8 RPL patients and
12 controls (Table 3). The cultures were passaged once, grown to
confluency, and then decidualized with 8-br-cAMP and MPA for
either 2 or 8 days. As expected, total ST2 transcript levels
increased markedly in differentiating HESCs and levels were
comparable between RPL and control groups (Fig. 10A). In
contrast, the induction of ST2L transcripts peaked at 2 days of
treatment with 8-br-cAMP and MPA in control samples (P,0.05).
This bi-phasic pattern of induction was absent in RPL samples and
ST2L mRNA levels remained elevated in cells decidualized for 8
days (P,0.001) (Fig. 10B). Secreted sST2 and IL-33 levels were
measured in additional RPL (n = 15) and non-RPL (n = 16)
primary cultures decidualized for 4 or 10 days. The media was
changed every 48 h. Interestingly, primary cultures from RPL
patients secreted significantly lower levels of sST2 upon prolonged
(day 10) decidualization (P,0.001) (Fig. 10C). Even more striking
was the difference in IL-33 secretion between the two clinical
groups. In control cultures, approximately 10-times more IL-33
was secreted by 4 days compared to 10 days of decidualization
whereas the reverse was true for RPL cultures (P,0.0001)
(Fig. 10D).
Next we examined if the prolonged pro-inflammatory response
in decidualizing HESCs from RPL patients impacted on embryo
implantation in the mouse uterus. Out of 40 embryos transferred
in each group, 16 (40%) and 21 (52%) implanted after uterine
exposure to secreted factors from undifferentiated cells and cells
decidualized for 4 day, respectively (Fig. 10E). This was
significantly lower when compared to the 29 (72.5%) embryos
that implanted following flushing with conditioned medium from
primary RPL cultures decidualized for 10 days (P,0.05).
Interestingly, although embryo implantation was least impaired
in response to exposure to signals of HESCs decidualized for 10
days, approximately 90% of pregnancies displayed defects in the
feto-maternal interface 3 days later (Table 4). Thus, while
paracrine signals from RPL cultures decidualized for 10 days fail
to render the endometrium refractory, the out-of-phase uterine
environment at implantation seems to compromise the subsequent
pregnancy trajectory.
Discussion
Gene ablation studies in mice have been instrumental in
identifying key implantation regulators. Within this growing
network of genes many encode secreted factors, including growth
factors (e.g. Hb-egf), cytokines (e.g. Lif, Il-1b, Prok1, and Il-11)
and various morphogens (e.g. Ihh, Wnt4, Bmp2) [1,38,39]. These
factors not only signal to the pre-implantation embryo but also
establish paracrine gradients that control differentiation of specific
cell types in a distinct temporal-spatial order. For example, Ihh
signaling, emanating from the receptive epithelium and acting on
the underlying stroma, is indispensable for both implantation and
decidualization [40,41]. Mesenchymal-epithelial signaling is
equally important for implantation. This was elegantly illustrated
by a recent study demonstrating that progesterone, acting on its
receptor in stromal cells, induces the basic helix-loop-helix
transcription factor Hand2 [42]. By suppressing the production
of fibroblast growth factors that mediate the mitogenic effects of
estrogen on the epithelium, Hand2 in stromal cells allows
neighboring epithelial cells to exit the cell cycle and to enter a
differentiation pathway leading to the window of implantation
[42]. Thus, sequential activation of bidirectional paracrine signal
cascades between the stromal and epithelial compartments in
murine endometrium triggers the receptive endometrial pheno-
type and couples it to the decidual response upon embryo
implantation [2,43].
Figure 9. IL-33 knockdown in decidualizing HESCs impairs embryo implantation. (A) Vas mated C57BL/6 female mice were subjected to
laparotomy and both uterine horns gently flushed with culture supernatant from primary HESC cultures first transfected with non-targeting (NT) or IL-
33 siRNA (si IL-33) and then decidualized for 4 (D4) with 8-bromo-cAMP and MPA. Ten embryos (equivalent to stage 3.5 d.p.c.) were then transferred
to the right horn. Each treatment group consisted of 5 animals. The number of implantation sites in the right horn was determined at 9.5 d.p.c.
Implantation was dramatically reduced following exposure to culture supernatant from IL-33 deficient D4 HESCs. ***P,0.001. (B) Macroscopic
appearance of uteri at 9.5 d.p.c. (Scale bar: 1 cm). (C) H&E staining of representative implantation sites. Upper panel shows a normal early pregnancy
following flushing of uterine lumen culture supernatant from primary HESCs transfected with NT siRNA. Note the placental (P) primordium, fusion of
allantois (A) to chorion, and fetal (F) tissue. Lower panel; exposure to culture supernatant from IL-33 deficient HESCs decidualized for 4 days (D4)
resulted in an array of pathological features in early pregnancy, including focal bleeding at the feto-maternal interface (arrows). Irregularity and
pinkness of the amniotic fluid suggest collapse of the amnion and coagulation of its content (*). (Scale bar: 100 mm).
doi:10.1371/journal.pone.0052252.g009
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Figure 10. Deregulated IL-33/ST2 activity in decidualizing HESCs from RPL subjects is associated with early pregnancy failure. (A &
B) Primary cultures, passaged once, from control (n = 12) and RPL (n = 8) subjects were treated with 8-Br-cAMP and MPA (cAMP/MPA) for 2 or 8 days.
Total ST2 and ST2L transcript levels, normalized to L19 mRNA, were measured and expressed in arbitrary units (A.U.). Horizontal bars indicate the
median expression in each group. Note the logarithmic y-axes. *P,0.05; ***P,0.001. (C & D) Additional cultures from control (n = 15) and RPL (n = 16)
subjects were treated with 8-Br-cAMP and MPA (cAMP/MPA). The medium was changed every 48 hours. Accumulated levels of secreted sST2 and IL-
33 were measured at 4 and 8 days of treatment. Horizontal bars indicate the median expression in each group. Note the logarithmic y-axes.
***P,0.001; ****P,0.0001. (E) The murine implantation model was used to examine the consequences of a prolonged and disordered pro-
inflammatory response in decidualizing HESCs from RPL patients. In each treatment group, a total of 40 embryos were transferred in 4 animals. The
number of implantation sites (left panel) in the right horn was determined 72 h after blastocyst transfer (equivalent of 6.5 d.p.c.). The right panel
shows a representative implantation sites. Note the hemorrhagic resorption (arrows) and poor decidualization response in the D0 and D10 HESC
supernatant treatment groups. (Scale bar: 100 mm).
doi:10.1371/journal.pone.0052252.g010
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Decidualization of the stromal compartment in the human
endometrium is equally tightly controlled. However, this differen-
tiation process is no longer under the primary control of an
implanting embryo, as is the case in most mammals. Instead, it is
triggered during the mid-secretory phase of each cycle in response
to local factors, such as prostaglandin E2, that activate the cAMP
pathway [5]. Once initiated, the phenotype is maintained as long
as progesterone levels remain high. We now show that cAMP
signaling drives the expression of IL-33 in HESCs whereas
progestins upregulate ST2 transcripts. The presence of IL-33 in
human endometrium is not unexpected as this cytokine is
abundantly expressed in various mucosal and epithelial barrier
tissues [28,44]. Its nuclear expression combined with the absence
of a peptide signal for export led to the notion that IL-33 is
released primarily upon tissue injury or infection and, through
binding to ST2L on immune cells, responsible for initiating tissue
inflammation [28,45]. Unexpectedly, we found that decidualizing
HESCs actively secrete IL-33. Notably, recent studies showed that
viable cells can release IL-33, for example in response to cellular
stretch or mechanical strain [46]. It is therefore not inconceivable
that the profound changes in cell shape and actin dynamics upon
decidualization trigger nuclear export and secretion of IL-33 via
an unconventional pathway. Binding of IL-33 to ST2L on the cell
surface of differentiating HESCs establishes an autocrine pathway
that drives an acute phase response, characterized by coordinated
induction of interleukins, chemokines, C-reactive protein and
several other inflammatory mediators. STL2 activity in decid-
ualizing cells is intrinsically self-limiting as IL-33 combined with
continuous progestin signaling decreases transmembrane receptor
levels and stimulates the secretion of the anti-inflammatory decoy
receptor sST2. Transition from the pro- to anti-inflammatory
phase of the decidual process is further characterized by
suppression of many pro-inflammatory genes below basal levels
in undifferentiated stromal cells and the induction of the Th2
cytokines IL-5 and IL-10.
Several lines of evidence indicated that activation of the IL-33/
ST2 pathway in HESCs is critical for a successful pregnancy. First,
only during the pro-inflammatory phase did differentiating HESC
secrete factors that heightened the expression of murine receptivity
genes, enabling efficient implantation of transferred mouse
blastocysts. Second, we found that implantation in the mouse
uterus was actively impaired upon exposure to signals from
undifferentiated HESCs, from decidualizing cells in the anti-
inflammatory phase, and from decidualizing cells first transfected
with IL-33 siRNA. Importantly, while some embryos did implant
under these conditions, a high proportion of the resultant
implantation sites exhibited pathological features, including focal
bleeding and excessive immune cell infiltration. Notably, mice
deficient in either ST2 [47] or IL-33 are reportedly fertile
(personal communication with Dr A McKenzie, University of
Cambridge), although early pregnancy events have to our
knowledge not yet been investigated in these animal models.
While speculative, this may relate to interspecies differences in
maternal versus embryonic control of the decidual process or point
towards a degree of redundancy in the primary trigger of the pro-
implantation inflammatory response. Third, we showed that
sequential activation of the IL-33/ST2L/sST2 axis is deregulated
in primary HESCs from RPL subjects and likely to cause a
prolonged window of implantation. Again, many implantation
sites showed pathological features, emphasizing that the peri-
implantation milieu has profound consequences for the subsequent
developmental trajectory of the conceptus. Thus, a prolonged and
disordered auto-inflammatory response in resident stromal cells
seems to cause considerable collateral damage, resulting in
bleeding, excessive recruitment of local immune cells, and
subsequent fetal demise. In keeping with our findings, aberrant
signaling from the IL-33/ST2L/sST2 axis was associated with late
Table 3. Patient characteristics and culture details.
qRT-PCR (Fig 10 A & B) Control RPL
Number of patients 12 8
Age (years) 3364.9 32.263.6
Live births 0.361 0.460.7
Miscarriages 0.160.3 5.662.2*
LMP 1765.6 16.264.5
Days in culture 1665.1 15.462.3
ELISA (Fig 10 C & D) Control RPL
Number of patients 16 15
Age (years) 3463.1 32.366.6
Live births 0.460.9 0.260.4
Miscarriages 0 7.064.7*
LMP 17.667.1 20.865.3
Days in culture 1565.3 15.364.6
The control group consisted of patients with male factor,peritoneal/tubal or
unexplained infertility. The data presented are means 6 standard deviation.
LMP = last menstrual period. *indicates P,0.001.
doi:10.1371/journal.pone.0052252.t003
Table 4. Analysis of murine implantation sites after exposure to soluble factors from HESCs.
Control subjects: Number of implantation sites examined Normal (%) Abnormal (%)
D0 (n = 9) 55.6 44.4
D4 (n = 28) 89.3 10.7
D10 (n = 26) 26.9 73.1
RPL subjects: Number of implantation sites examined Normal (%) Abnormal (%)
D0 (n = 28) 14.3 85.7***
D4 (n = 18) 72.2 27.8*
D10 (n = 18) 11.1 88.9
Abnormal implantation sites were defined as those that had excessive focal bleeding, immune cell infiltration, obviously small for gestational age, or twin implantation.
The incidence of abnormal implantation sites in the mouse uterus was significantly higher following exposure to soluble factors secreted by HESCs at D0 and D4 from
RPL compared to control subjects. ***indicates P,0.001;*indicates P,0.05.
doi:10.1371/journal.pone.0052252.t004
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pregnancy complications such as pre-eclampsia [48] and miscar-
riage [49].
RPL, here defined as 3 or more consecutive miscarriages, is a
prevalent disorder that affects 1–2% of couples [50,51]. It is a
cause of considerable physical and psychological morbidity and
associated with increased likelihood of obstetric complications and
adverse perinatal outcome in a subsequent ongoing pregnancy
[51]. Our findings confirm that the cellular response to identical
differentiation signals is profoundly divergent between primary
cultures established from RPL and control subjects. Further, the
data provide novel insights into the nature and pathological
consequences of aberrant decidualization, although the underlying
molecular mechanism requires further elucidation. Emerging
evidence indicates that profound changes in chromatin structure,
exemplified by genome-wide redistribution of transcriptionally
repressive and permissive histone marks, precede the expression of
a decidual phenotype in HESCs [52]. Hence, it is possible that the
primary defect in RPL may lie in epigenetic programming of
endometrial stromal cells, or their bone marrow-derived stem/
progenitor cells [53].
In summary, by restricting the window of implantation, the
continuously changing endometrial environment is aligned to meet
the requirements of an implanting blastocyst. Prolonged or
unfettered endometrial receptivity carries an obvious risk of
implantation of developmentally delayed or compromised embry-
os [13]. Further, asynchrony between endometrial and embryo
development in early pregnancy may trigger a spectrum of
pathological events, leading to miscarriage or predispose for
obstetrical complications associated with defective placentation,
such as pre-eclampsia and fetal growth restriction [12,14]. Our
findings show that uterine receptivity is controlled by the
activation of autoregulatory feedback loops in decidualizing
stromal cells underlying the luminal epithelium that trigger the
sequential expression of pro- and anti-inflammatory gene
networks. While our observations suggest that stromal cells can
exert this function independently of local immune cells, comple-
mentation experiments are needed to define the regulatory roles of
other endometrial cell types during the implantation process. We
also provided evidence that failure of differentiating HESCs to
transit from a pro-receptive to a post-implantation phenotype
predisposes for subsequent pregnancy failure. Clinically, the IL-
33/ST2 pathway is considered a major novel target for
therapeutic interventions across a range of diseases, including
Alzheimer’s disease [54], helminth infections [55], cardiovascular
disease [56], obesity [57], asthma [58] and other autoimmune
disorders [59,60]. Our findings suggest that targeting the same
pathway in the uterus is a promising strategy to regulate
endometrial receptivity.
Supporting Information
Figure S1 Schematic representation. ST2 primer pairs
used to amplify all Total-ST2 transcripts (T-ST2) or the
transmembrane ST2L (TM-ST2) transcripts.
(TIFF)
Figure S2 Il-33 knockdown in HESCs decidualized for 2
days triggers an inflammatory response akin to that
seen in cells decidualized for 8 days. (A) Number of
transcripts significantly up- or down-regulated in each of the
indicated categories upon decidualization for 2 or 8 days (D2 and
D8, respectively) compared to undifferentiated cells. (B) Number of
transcripts significantly up- or down-regulated in each of the
indicated categories after 2 days of decidualization of primary
HESCs cultures transfected with either non-targeting (NT) or IL-
33 siRNA (si IL-33).
(TIF)
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